Anti-leukemic effects of PPARγ ligands. (1st April 2018)

• Record Type: Journal Article
• Authors: Ryu, Somi; Kim, Dae Seong; Lee, Myoung Woo; Lee, Ji Won; Sung, Ki Woong; Koo, Hong Hoe; Yoo, Keon Hee
• Is Part Of: Cancer letters. Volume 418(2018)
• Page Start: 10
• Page End: 19
• Publication Date: 2018-04-01
• Subjects: Peroxisome proliferator-activated receptor γ -- Peroxisome proliferator-activated receptor γ ligand -- Leukemia -- Anti-leukemic effect; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2018.01.020
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: The peroxisome proliferator-activated receptor (PPAR) γ, a subtype of PPARs, is a member of the nuclear receptor family. PPARγ and its ligands contribute to various types of diseases including cancer. Given that currently developed therapies against leukemia are not very effective or safe, PPARγ ligands have been shown to be a new class of compounds with the potential to treat hematologic malignancies, particularly leukemia. The capability of PPARγ ligands to induce apoptosis, inhibit proliferation, and promote differentiation of leukemia cells suggests it has significant potential as a drug against leukemia. However, the specific mechanisms and molecules involved are not well-understood, although a number of PPARγ ligands with anti-leukemic effects have been identified. This may explain why PPARγ ligands have not been widely evaluated in clinical trials. To fill the gaps in the lack of understanding of specific anti-leukemic processes of PPARγ ligands and further adapt these molecules as anti-leukemic agents, this review describes previous studies of the anti-leukemic effects of PPARγ ligands. Highlights: PPARγ ligands show a variety of anti-leukemia effects (e.g., inducing apoptosis). With other compounds, PPARγ ligands possess enhanced anti-leukemia activities. PPARγ ligands are particularly promising as anti-leukemic agents.